PD-1 gene polymorphic variation is linked with first symptom of disease and severity of relapsing-remitting form of MS

被引:22
作者
Pawlak-Adamska, Edyta [1 ]
Nowak, Oskar [2 ]
Karabon, Lidia [1 ]
Pokryszko-Dragan, Anna [3 ]
Partyka, Anna [1 ]
Tomkiewicz, Anna [1 ]
Ptaszkowski, Jakub [4 ]
Frydecka, Irena [1 ]
Podemski, Ryszard [3 ]
Dybko, Jaroslaw [5 ]
Bilinska, Malgorzata [3 ]
机构
[1] Polish Acad Sci, Hirszfeld Inst Immunol & Expt Therapy, Dept Expt Therapy, R Weigl Str 12, PL-53114 Wroclaw, Poland
[2] Adam Mickiewicz Univ, Inst Anthropol, Dept Human Evolut Biol, Umultowska 89, PL-61614 Poznan, Poland
[3] Wroclaw Med Univ, Dept Neurol, Borowska 213, PL-50566 Wroclaw, Poland
[4] Wroclaw Med Univ, Fac Hlth Sci, Dept Clin Biomech & Physiotherapy Motor Syst Diso, Grunwaldzka 2, PL-50355 Wroclaw, Poland
[5] Med Univ, Dept Hematol Blood Neoplast Dis & Bone Marrow Tra, Pasteura 4, PL-50367 Wroclaw, Poland
关键词
Multiple sclerosis; PD-1; gene; PD-15; Diplopia; Pyramidal signs; RRMS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; RHEUMATOID-ARTHRITIS; MULTIPLE-SCLEROSIS; PROGRAMMED DEATH-1; PDCD1; GENE; T-CELLS; REGULATORY POLYMORPHISM; ANKYLOSING-SPONDYLITIS; IMMUNE REGULATOR;
D O I
10.1016/j.jneuroim.2017.02.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS), where inflammation, demyelination together with the axonopathy are the cardinal features on pathologic ground, with a combined genetic and environmental background. The associations of PD-1 single nucleotide polymorphisms (SNPs): PD-1.3 (in intron 4), PD-1.5 and PD-1.9 (both in exon 5) with clinical manifestation of MS in 479 south Polish individuals including 203 MS patients were analyzed. Presence of PD-1.5 T allele was linked with the first manifestations of disease: diplopia and pyramidal signs-favored pyramidal signs but protected against of diplopia development. Farther, PD-1.3G/PD-1.5C/PD-1.9C haplotype significantly favored whereas GTC protected against diplopia. Besides, GTT haplotype strongly favored non-severe RRMS outcome and ATC haplotype was specific only for these MS patients. Our population-based case-control study, investigating selected three PD-1 SNPs: PD-1.3, PD-1.5 and PD-1.9, revealed that polymorphic variation may be rather disease-modifying than MS risk factor. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:115 / 127
页数:13
相关论文
共 49 条
[1]  
[Anonymous], 2014, INT J SCI, DOI DOI 10.7511/DLLGXB201401019
[2]   HLA, PTPN22 and PD-1 associations as markers of autoimmunity in neuromyelitis optica [J].
Asgari, N. ;
Nielsen, C. ;
Stenager, E. ;
Kyvik, K. O. ;
Lillevang, S. T. .
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (01) :23-30
[3]   Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: Attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses [J].
Bennett, F ;
Luxenberg, D ;
Ling, V ;
Wang, IM ;
Marquette, K ;
Lowe, D ;
Khan, N ;
Veldman, G ;
Jacobs, KA ;
Valge-Archer, VE ;
Collins, M ;
Carreno, BM .
JOURNAL OF IMMUNOLOGY, 2003, 170 (02) :711-718
[4]   Genetic, Immunologic, and Immunohistochemical Analysis of the Programmed Death 1/Programmed Death Ligand 1 Pathway in Human Systemic Lupus Erythematosus [J].
Bertsias, George K. ;
Nakou, Magda ;
Choulaki, Christlanna ;
Raptopoulou, Amalia ;
Papadimitraki, Eva ;
Goulielmos, George ;
Kritikos, Herakles ;
Sidiropoulos, Prodromos ;
Tzardi, Maria ;
Kardassis, Dimitris ;
Mamalaki, Clio ;
Boumpas, Dimitrios T. .
ARTHRITIS AND RHEUMATISM, 2009, 60 (01) :207-218
[5]   Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy [J].
Blank, C ;
Gajewski, TF ;
Mackensen, A .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (04) :307-314
[6]   Blockade of programmed death-1 Ligands on dendritic cells enhances T cell activation and cytokine production [J].
Brown, JA ;
Dorfman, DM ;
Ma, FR ;
Sullivan, EL ;
Munoz, O ;
Wood, CR ;
Greenfield, EA ;
Freeman, GJ .
JOURNAL OF IMMUNOLOGY, 2003, 170 (03) :1257-1266
[7]   PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis [J].
Carter, Laura L. ;
Leach, Michael W. ;
Azoitei, Mihai L. ;
Cui, Junqing ;
Pelker, Jeffrey W. ;
Jussif, Jason ;
Benoit, Steve ;
Ireland, Gretchen ;
Luxenberg, Deborah ;
Askew, G. Roger ;
Milarski, Kim L. ;
Groves, Christopher ;
Brown, Tom ;
Carito, Brenda A. ;
Percival, Karen ;
Carreno, Beatriz M. ;
Collins, Mary ;
Marusic, Suzana .
JOURNAL OF NEUROIMMUNOLOGY, 2007, 182 (1-2) :124-134
[8]   Constitutive Neuronal Expression of the Immune Regulator, Programmed Death 1 (PD-1), Identified During Experimental Autoimmune Uveitis [J].
Chen, Ling ;
Pai, Vicky ;
Levinson, Ralph ;
Sharpe, Arlene H. ;
Freeman, Gordon J. ;
Braun, Jonathan ;
Gordon, Lynn K. .
OCULAR IMMUNOLOGY AND INFLAMMATION, 2009, 17 (01) :47-55
[9]   The PD-1/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-gamma [J].
Cheng, Xiaodong ;
Zhao, Zhao ;
Ventura, Elvira ;
Gran, Bruno ;
Shindler, Kenneth S. ;
Rostami, Abdolmohamad .
JOURNAL OF NEUROIMMUNOLOGY, 2007, 185 (1-2) :75-86
[10]   Soluble CTLA-4 receptor an immunological marker of Graves' disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms [J].
Daroszewski, Jacek ;
Pawlak, Edyta ;
Karabon, Lidia ;
Frydecka, Irena ;
Jonkisz, Anna ;
Slowik, Miroslaw ;
Bolanowski, Marek .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2009, 161 (05) :787-793